基于氨酸的响应光的长效水凝,用于眼内输送螺旋诺拉克
Sai Shreya Cheruvu1, Shruthi Merugu1, Manisha Malani1
1Translational Pharmaceutics Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Hyderabad Campus, Jawahar Nagar, Kapra Mandal, Medchal District, Telangana 500078, India.
International journal of biological macromolecules
|August 1, 2025
概括
一种新型的对光敏感的水凝可以为糖尿病视网膜病变 (DR) 提供螺旋 (SPL). 这种持续的药物输送平台显示了长期治疗的前景,减少了频繁注射眼睛的需要.
科学领域:
- 眼科医生 眼科 眼科
- 生物材料科学 生物材料科学
- 药理学 药理学是指药理学的学科.
背景情况:
- 与年龄相关的黄斑变性 (AMD) 和糖尿病视网膜病变 (DR) 等状视网膜疾病会导致不可逆转的视力丧失.
- 非VEGF途径,包括氨酸- ангиотензин-阿尔多斯特系统 (RAAS),为DR提供了替代的治疗点,特别是在对抗VEGF疗法的不响应者.
- 在DR中升与视网膜血管生成和炎症有关,这表明RAAS抑制剂如螺旋 (SPL) 作为潜在的治疗方法.
研究的目的:
- 开发一种持续药物输送系统,用于治疗糖尿病视网膜病变 (DR).
- 创建一个响应光的,在现场凝的水凝仓库,用于长时间的眼部药物释放.
- 评估SPL装载水凝的体内安全性和有效性,用于长效的静脉内药物输送.
主要方法:
- 一种对光敏感的甲基化氨酸 (MEHA) 聚合物的合成.
- 开发一个in situ凝水凝仓库,在UV交叉连接时持续释放SPL.
- 在90天内进行的体外药物释放研究和在体内眼部停留研究 (>60天).
- 在DR模型中对SPL加载的水凝进行体内安全性和有效性评估.
主要成果:
- 响应光的水凝在90天内在体外显示了SPL的持续释放.
- 在体内研究证实了水凝在眼睛中停留超过60天.
- 在糖尿病视网膜病变模型中,SPL装载的水凝在体内显示出安全性和有效性.
结论:
- 一种对光敏感的MEHA水凝使得持续的静脉内输送螺旋 (SPL) 成为可能.
- 该平台为糖尿病视网膜病变 (DR) 提供了一种有前途的长效药物输送策略,可能减少药物输送频率.
- 开发的水凝证明了安全性和有效性,支持其用于慢性眼病管理.
相关概念视频
Drug Delivery: Miscellaneous Routes
468
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
468
Open Angle Glaucoma: Treatment
570
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
570


